Purpose: To assess changes in Ocular Response Analyzer (ORA) waveforms after UVA/riboflavin corneal collagen cross-linking (CXL) using investigatorderived and manufacturer-supplied morphometric variables in patients with keratoconus (KC) and postrefractive surgery ectasia. Design: Prospective randomized trial of a standard epithelium-off CXL protocol. Participants: Patients with progressive KC (24 eyes of 21 patients) or postrefractive surgery ectasia (27 eyes of 23 patients) were enrolled. Methods: Replicate ORA measurements were obtained before and 3 months after CXL. Pretreatment and posttreatment waveform variables were analyzed for differences by paired Student t tests using measurements with the highest waveform scores. Main Outcome Measures: Corneal hysteresis, corneal resistance factor, 37-s generation manufacturer-supplied ORA variables, and 15 investigatorderived ORA variables. Results: No variables were significantly different 3 months after CXL in the KC group, and no manufacturer-supplied variables changed significantly in the postrefractive surgery ectasia group. Four custom variables (ApplanationOnset-Time, P1P2avg, Impulse, and Pmax) increased by small but statistically significant margins after CXL in the postrefractive surgery ectasia group. Conclusions: Changes in a small subset of investigator-derived variables suggested an increase in corneal bending resistance after CXL. However, the magnitudes of these changes were low and not commensurate with the degree of clinical improvement or prior computational estimates of corneal stiffening in the same cohort over the same period. Available air-puff-derived measures of the corneal deformation response underestimate the biomechanical changes produced by CXL.
K eratoconus (KC) and postrefractive surgery ectasia are characterized by progressive corneal distortion and vision loss related to a decrease in corneal biomechanical integrity. Corneal collagen cross-linking (CXL) has been introduced as a treatment that specifically targets this biomechanical weakness [1] [2] [3] and confers a stiffening effect through incompletely understood mechanisms that include formation of covalent bonds within and between collagen chains. 3 Clinically, CXL has been shown to be effective in stabilizing ectatic disease, 2, 4 and in many patients, reducing corneal topographic steepness 2, 5, 6 and improving visual acuity. 5, 6 The Ocular Response Analyzer (ORA; Reichert Ophthalmic Instruments, Buffalo, NY) is a modified noncontact pneumotonometer that measures aspects of the corneal biomechanical response during an air-puff perturbation. Corneal hysteresis (CH) and corneal resistance factor (CRF) are two standard ORA variables that reflect the viscoelastic damping capabilities and elastic resistance of the cornea, 7 and both have been shown to be significantly lower in eyes with ectatic disease. [8] [9] [10] Corneal collagen cross-linking has been associated with an increase in corneal elastic modulus in ex vivo studies 1, 2, [11] [12] [13] [14] and in an inverse computational modeling study that derived stiffening effect from clinical CXL results. 15 Although several reports have demonstrated the lack of significant changes in CH and CRF after CXL, [16] [17] [18] [19] [20] Spoerl et al. 18 reported an increase in the second-generation ORA variable p2area-the area under the second of the two infrared signal applanation curves-after CXL.
Our group has described a set of custom ORA variables that characterize the temporal, applanation signal intensity, and pressure features of the corneal deformation response produced by the ORA. 21 A subset of these investigator-derived variables was more sensitive and specific than CH and CRF for discriminating eyes with KC from normal eyes and described dynamic features of the deformation response that are consistent with a biomechanically compromised cornea. 21 This study aims to investigate biomechanical changes after standard CXL with riboflavin/ultraviolet-A (UVA) in patients with KC and postrefractive surgery ectasia using standard and second-generation manufacturer-supplied ORA variables and our panel of custom variables.
SUBJECTS AND METHODS

Patient Selection
Patients with progressive KC or postrefractive corneal ectasia were enrolled in a prospective, randomized, single-site clinical trial to determine the safety and efficacy of the UV-X system (IROC, Zurich, Switzerland) for performing CXL. The study was a physician-sponsored Investigational New Drug performed under the guidelines of the Food and Drug Administration and approved by the Emory Investigational Review Board (Clinical Trials.gov identifier: NCT00567671). All participants signed a written informed consent for research.
Candidates underwent a complete history and ophthalmologic examination. Criteria for inclusion were (1) age 14 years or older, (2) diagnosis of corneal ectasia after corneal refractive surgery including laser in situ keratomileusis (LASIK), photorefractive keratectomy, or Epi-LASIK, (3) evidence of progressive KC is defined as an increase of $1.00 D in the steepest keratometry value (sim-K), an increase of $1.00 D in regular astigmatism evaluated by subjective manifest refraction, a myopic shift (decrease in the spherical equivalent) of $0.50 D on subjective manifest refraction, and/or a decrease of $0.1 mm in the back optical zone radius in rigid contact lens wearers where other information is not available; (4) axial topography or Pentacam consistent with KC or corneal ectasia, (5) presence of one or more of the following slitlamp findings: Fleischer ring, Vogt striae, corneal thinning, and or corneal scarring, (6) maximum keratometric curvature value (Kmax) of $47.00 D, (7) I-S ratio greater than 1.5 on the Pentacam map or Orbscan map, and (8) best spectacle-corrected visual acuity worse than 20/20 (,55 letters on ETDRS chart), and/or (9) willingness to comply with schedule for follow-up visits. Patients were excluded for (1) the presence of normal topographic maps or classification as KC suspect, (2) history of corneal surgery or the insertion of intrastromal ring segments, (3) corneal pachymetry #400 mm at the thinnest point measured by Pentacam in the eye to be treated when isotonic riboflavin solution was to be used or #300 mm when hypotonic riboflavin was to be used, provided that the corneal thickness after treatment with the riboflavin solution is greater than 400 mm, (4) history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, or corneal dystrophy, and so on), scar, or chemical injury, (5) nystagmus, (6) active pregnancy, plan to become pregnant, or lactation during the course of the study, and/or (7) known allergy to study medications.
After initial evaluation, eyes that met the criteria were randomized to either the treatment or control group. Only eyes in the treatment group were evaluated in this study. A total of 24 eyes of 21 patients with KC and 27 eyes of 23 patients with postrefractive surgery ectasia qualified for analysis.
Surgical Procedure
The surgical procedures were performed by two surgeons (J.B.R. and R.D.S.). After instillation of topical proparacaine 0.5% (Alcaine; Alcon, Fort Worth, TX), the central 9 mm of the corneal epithelium was removed using a blunt knife to facilitate riboflavin diffusion into the cornea. Corneal thickness measurements were obtained with ultrasound pachymetry (DGH 550 Pachette 2; DGH Technology Inc., Exton, PA) before and after the epithelium removal to assure a residual corneal thickness of at least 350 mm. After epithelial debridement was performed, 1 drop of riboflavin 0.1% ophthalmic solution was instilled topically every 2 min for 30 min. At the end of the 30-min riboflavin pretreatment period, the eye was examined with blue light for the presence of a yellow flare in the anterior chamber as an indicator of adequate riboflavin saturation of the corneal tissue. If the corneal thickness was less than 400 mm, 2 drops of hypotonic riboflavin 0.1% were instilled every 10 to 15 sec until the corneal thickness increased to at least 400 mm.
A lid speculum was placed between the lids of the eye to be treated, and the eye was aligned under the UV-X system. The UVA irradiation was applied at a 50 mm working distance for 30 min using a 3 mW/cm 2 irradiance. The correct aperture setting was selected according to the size of the eye (7.5, 9.5, or 11 mm), and the eyes were irradiated for 30 min during which instillation of riboflavin continued at 1 drop every 2 min.
A bandage contact lens was placed immediately after the treatment and removed 4 to 7 days later. Postoperative medications consisted of moxifloxacin 0.5% (Vigamox; Alcon) 4 times a day for 1 week, prednisolone 1% ophthalmic suspension (Pred Forte; Allergan, Irvine, CA) 1 drop 4 times a day for 2 weeks, and ketorolac tromethamine 0.4% (Acular LS; Allergan) 1 drop 4 times a day for up to 4 days as needed for pain.
Examination and Measurements
Pentacam (Oculus Inc., Lynnwood, WA), Orbscan corneal topography (Bausch & Lomb, Rochester, NY), OPD-Scan (Nidek Inc., Fremont, CA), and ORA measurements (Reichert Inc., Depew, NY) were performed at the screening visit and 3 months after the cross-linking treatment.
The ORA method of operation has been previously described in detail. 7 Briefly, an air jet generates a force directed at the central cornea that causes deformation of the cornea into a slight concavity followed by a return to its preperturbation convex shape. During the cycle, applied pressure and the intensity of an infrared signal that reflects on the cornea are measured. The measurements with highest waveform scores, an indicator of measurement quality, were used for analysis.
Manufacturer-Provided Ocular Response Analyzer Variables
The ORA software provides 37-sec generation variables in addition to the standard CH and CRF values (Table 1) . 20 Corneal hysteresis is calculated as the difference between the pressure values at the ingoing and outgoing corneal applanation events. Corneal resistance factor is a linear combination of these values, P12(k·P2), where k is an empirically derived constant with a value of 0.7 designed to maximize the dependence of CRF on central corneal thickness. This formulation also biases CRF toward the pressure associated with the ingoing applanation event and thus the initial elastic resistance of the cornea to an air puff.
Custom Ocular Response Analyzer Variables
Fifteen custom variables were derived from aspects of the ORA signal and have been previously described in detail. 21 Briefly, variables are classified based on their relationship to the ORA applanation signal intensity, applied pressure, temporal aspects of the infrared signal, or a combination of these features ( Table 2) . Custom code was developed to compute variable values using exported time-resolved infrared signal and pressure data from the ORA.
Statistical Analysis
Paired two-tailed Student t tests were performed to compare ORA variables before and 3 months after CXL. A correction of the significance criterion was performed according to the Bonferroni method. For a total of 54 comparisons of ORA variables, an adjusted P value of 0.05/54=0.0009 was considered significant. Demographic variables between groups were compared with non-paired t tests with a significance criterion of P,0.05, and clinical disease severity measures before and after CXL were compared using paired t tests (P,0.05).
RESULTS
Subject demographics are described in Table 3 . Age was not different between groups. Preprocedural and postprocedural clinical features are described in Table 4 . Three months after CXL, both KC and postrefractive surgery ectasia patients demonstrated increased visual acuity and decreases in the tomographic thickness measured at the cornea's thinnest point.
Cornea 
SlopeUp
Positive slope of the first applanation peak, from inflection point to peak
Rate of achieving peak planarity
SlopeDown Negative slope of the first applanation peak, from peak to inflection point A summary of all variable measures before and after CXL in the KC and postrefractive surgery ectasia groups is provided in Table 5 . Mean CH and CRF were not statistically different in either group (Table 5 ). No variables were statistically different at 3 months after cross-linking in patients with KC. No manufacturer-supplied variables were statistically different in the postrefractive ectasia group. However, 4 of the 15 investigator-derived variables (Applanatio-nOnsetTime, P1P2avg, Impulse, Pmax) did demonstrate a significant increase after CXL (Table 6 ).
DISCUSSION
Corneal cross-linking is the only treatment for ectatic disease that directly targets alteration of intrinsic biomechanical properties. It has been shown to improve vision, 5 halt topographic progression, and in many patients, affect a degree of topographic regression of disease. 2, 4, 19 However, measurements such as visual acuity, topography, and tomography are secondary measures of the intended effect of CXL. Direct clinical assessment of CXL-induced changes in corneal biomechanical properties has been more challenging.
The ORA is a commercially available device that allows for in vivo characterization of the corneal deformation response to an air-puff stressor. In this study, we investigated the changes that CXL confers on the dynamic behavior of KC and postrefractive ectasia corneas through the analysis of novel waveform-derived ORA variables related to pressure, applanation signal intensity, or stress response time.
Previous studies have not found significant changes in CH and CRF in response to CXL beyond 1 month from the procedure. Vinciguerra et al. 20 found that CH and CRF significantly increased intraoperatively and through the postprocedural 1-month point; but, similar to our study, these standard variables were not significantly different at the 3-month mark or beyond.
Likewise, no change was found 6 months post-CXL in a study of 56 KC eyes, 19 and Spoerl et al. 18 also found no significant change in CH or CRF 1 year after CXL. These and other published results suggest that CH and CRF may not be sensitive enough measures of biomechanical stiffening after CXL.
In our analysis, no variables related to the applanation signal intensity, which relies on specular reflection from the precorneal tear film, were significantly different after CXL in either therapeutic group. This may be related to measurement variability related to early epithelial remodeling or intrinsic interindividual variability in the epithelial remodeling process that also could reduce statistical power to detect a difference. Vinciguerra et al. similarly showed no significant difference in the peak 1 and 2 amplitudes in the immediate postoperative period. However, by month 6 and 12 after cross-linking, the peaks had significantly increased. 20 Similarly, p2area had significantly increased by 35% 1 year after CXL in an investigation of 50 KC eyes. 18 The current clinical study design did not include acquisition of ORA measurements beyond 3 months, so comparison with 1 year results should be performed with caution.
This study does, for the first time, demonstrate statistically significant increases in certain pressure-related variables and a single temporal response variable after CXL in the postrefractive surgery ectasia group. P1P2avg-the average value of the pressures at the first and second applanation points-increased by 7%. Impulse-the area under the pressure curve-increased by 4%, and the applied pressure peak (Pmax) increased by 5%. Ap-planationOnsetTime, or the time it takes to achieve the first applanation event, increased by 3%. The directionality of these changes is consistent with increased bending resistance and shows that at 3 months after CXL, these variables have greater sensitivity than other ORA variables for detecting evidence of a stiffening effect conferred by CXL in postrefractive surgery ectasia eyes. However, the magnitudes of these changes were not commensurate with the degree of clinical improvement seen over the same follow-up period. The degree of change in these ORA variables was also less than the post-CXL changes observed in ex vivo studies. After standard CXL in porcine eyes, Young modulus has been found to increase by 100% 22 and by a factor of 1.8 2 when tested with a biomaterial load frame. One study examining rabbit eyes showed a 101.45% increase in Young modulus after standard CXL, 13 and another showed an increase of 79.3% immediately after the procedure, 78.4% at 3 months, and 87.4% at 8 months. 23 With an optical coherence elastography technique, human donor corneas had a 33% mean increase in relative lateral stiffness after CXL. 24 IOPcc, cornea-compensated intraocular pressure; IOPg, intraocular pressure-Goldmann; SD, standard deviation. CDVA, total number of letters seen with best spectacle correction and distance target; thinnest CT, corneal thinnest point measured by Scheimpflug tomography; CXL, corneal collagen cross-linking; D, diopters; Kmax, steepest corneal curvature measured by Scheimpflug tomography; SD, standard deviation; SE, spherical equivalent manifest refraction; Sim-K, mean Sim-Ks measured by Scheimpflug tomography.
Through inflational experiments, the theoretical computations of Young modulus increased by 1.58·24 hr after CXL in porcine corneas. 12 Of particular relevance to the current results, prior computational estimates from this research group used inverse finite element modeling to deduce a mean stiffening of 1.8· in 16 KC and postrefractive surgery ectasia eyes from the same study cohort presented here. 15 These estimates were obtained over the same follow-up period and indicate a high level of effective corneal stiffening in KC eyes, despite the absence of any significant changes in ORA-derived variables in the same group.
Interestingly, ORA variables were not significantly different in the KC group. The pathophysiological differences in postrefractive surgery ectasia and KC could be a contributing factor, but low measurement sensitivity and high interindividual variability could be important factors. At least one contributing factor to the development of postrefractive ectasia is a low residual bed thickness. [25] [26] [27] If the biomechanically affected area in postrefractive surgery ectasia is larger or more diffuse than the typical focal region of weakening in keratoconus, CXL may result in a larger area of relative stiffening. Because the ORA samples a central 3 mm zone of the cornea, these more widespread changes might be more likely to influence ORA-derived responses to the extent required for statistical significance. Intraocular pressure has been shown to influence the cornea's biomechanical response, with higher IOP correlating with stiffer behavior. 28 Although we did not stratify groups by pre-CXL IOP in this study, we have previously shown that IOP has a small influence on our custom ORA variables. 21 Furthermore, normalization of a custom variable by IOPcc in that study led to no change in the performance of the variable as a predictor of disease. 21 Thus, differences in IOP did not seem to significantly confound the discriminative value of these custom ORA variables. Data on IOP changes after CXL, as measured by the ORA, have varied from study to study. Vinciguerra et al. 20 found that neither IOPcc nor IOPg changed after CXL, whereas both had increased in the 1-month postprocedural period in a separate evaluation before returning to baseline at 6 months. 16 Contrarily, Sedaghat et al. 19 found IOPcc to decrease at 6 months, although the absolute change was less than 1 mm Hg. Our study found that IOPg did not change after CXL in KC but increased in the postrefractive ectasia group. Measurements of IOPcc increased in both groups, and the maximum change for any patient was 1.5 mm Hg. The variability in IOPcc trends after CXL may be attributable to the limited range under which IOPcc is accurate. The ORA's corneal-compensated IOP was designed to be less sensitive to reductions in corneal properties based on empirical data 29 comparing pre-LASIK and post-LASIK eyes, where true IOP was assumed to not change. Cornea-compensated intraocular pressure was not derived from measurements in pathologic corneas or in post-CXL corneas with increased corneal stiffness where the conditions of the original calibration are not fully met. Consequently, using IOPcc as a normalizing "true IOP" value has not been validated in the setting of CXL, and the assumption is made that true IOP in these patients has not changed significantly 3 months after CXL.
In summary, this study demonstrated changes in novel custom ORA variables after CXL that are consistent with an increase in bending resistance 3 months after CXL in postrefractive ectasia corneas but not KC. The low sensitivity of these air-puff-derived response variables illustrates the importance of more sensitive measures of corneal biomechanical change for assessing the material effects of collagen stiffening treatments. CXL, corneal collagen cross-linking.
